Pancreatic Cancer's Glimmer of Hope: A Breakthrough's Bittersweet Taste The US Food and Drug Administration has approved daraxonrasib, marketed as Rasonque, marking a significant milestone in the fight against pancreatic cancer.
The treatment has shown unprecedented results in clinical trials, offering a glimmer of hope to patients and their families who have long been ravaged by this deadly disease.
Pancreatic cancer is still a formidable foe, with one of the highest mortality rates among major cancers. More than half of those diagnosed die within three months of receiving the diagnosis.